Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Sana Biotechnology

Sana Biotechnology (NASDAQ: SANA) insider transactions

In the twelve months to 10 November 2026, executives and directors of Sana Biotechnology reported no open-market sales and no open-market purchases, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Sana Biotechnology shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
5 October 2026Bishop Hans EdgarDirectorGrant or award+8,680—5,863,480Form 4
27 August 2026Patel Dhavalkumar DhirajlalEVP, Chief Scientific OfficerShares withheld for tax−41,158$4.11183,352Form 4
26 August 2026Patel Dhavalkumar DhirajlalEVP, Chief Scientific OfficerOption exercise+125,000—224,510Form 4
6 July 2026Bishop Hans EdgarDirectorGrant or award+6,297—5,854,800Form 4
6 April 2026Bishop Hans EdgarDirectorGrant or award+7,763—5,848,503Form 4
9 March 2026Wyrick Susan D.See RemarksShares withheld for tax−3,342$3.13197,241Form 4
9 March 2026Wyrick Susan D.See RemarksShares withheld for tax−1,045$3.10196,196Form 4
9 March 2026Harr StevePresident & CEOShares withheld for tax−11,526$3.137,957,070Form 4
9 March 2026Harr StevePresident & CEOShares withheld for tax−12,819$3.107,944,251Form 4
7 March 2026Wyrick Susan D.See RemarksOption exercise+3,250—200,583Form 4
7 March 2026Harr StevePresident & CEOOption exercise+50,000—7,968,596Form 4
6 March 2026Wyrick Susan D.See RemarksOption exercise+10,416—197,333Form 4
6 March 2026Harr StevePresident & CEOOption exercise+41,666—7,918,596Form 4
3 March 2026Wyrick Susan D.See RemarksShares withheld for tax−491$3.91186,917Form 4
2 March 2026Wyrick Susan D.See RemarksOption exercise+1,525—187,408Form 4
5 January 2026Bishop Hans EdgarDirectorGrant or award+6,157—5,840,740Form 4
5 January 2026Wyrick Susan D.See RemarksShares withheld for tax−2,407$4.27185,883Form 4
2 January 2026Wyrick Susan D.See RemarksOption exercise+7,500—188,290Form 4
15 December 2025Wyrick Susan D.See RemarksShares withheld for tax−873$5.22180,790Form 4
13 December 2025Wyrick Susan D.See RemarksOption exercise+3,400—181,663Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Sana Biotechnology page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.